BESHENKOVICHI, 13 July (BelTA) – The Lithuanian private sector shows a strong interest in the Belarusian pharmaceutics industry, BelTA learned from Linas Valentukevicius, member of the Board of Directors of Avia Solutions Group, member of the Board of Directors of Nativita Company.
The international R&D and manufacturing complex Nativita was opened in Beshenkovichi, Vitebsk Oblast on 13 July. It is a unique project because representatives of four countries, including Lithuania, are involved in it.
Linas Valentukevicius mentioned the interest of the Lithuanian private sector in Belarus. As far as investments in Nativita are concerned, the Belarusian market and the country's experience in pharmaceutics were closely examined before the investments were made. The analysis proved that Belarus occupies a decent position in the development of pharmaceutical science and in university education. “We invest not only money in Nativita. We bring a lot of experience in administration, international ties, and markets. We see this company as an international one,” said the investor.
Nativita is modern high-technology facility designed and built with assistance of expert consultants from the European Union and the Commonwealth of Independent States. Nativita Company can make medications as tablets, capsules, and liquids in compliance with the European standard GMP. The pharmaceutical enterprise is primarily designed to research and make innovative medications for treating oncological diseases.
